By Rose Krebs ( February 19, 2019, 9:15 PM EST) -- The Delaware chancellor on Tuesday awarded $70,000 for legal costs to an investor trust that filed a proposed class action over flawed approvals issued in connection with DAVA Pharmaceuticals Inc.'s $600 million merger with Endo Pharmaceuticals Inc., finding that the deficient approvals had "potential to wreak havoc later."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.